Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Non-access-related infections in chronic dialysis patients

INTRODUCTION

In addition to infections associated with dialysis access devices, patients with end-stage renal disease (ESRD) who require renal replacement therapy may be susceptible to non-access-related infections. Diagnostic strategies for these infections are similar to those used for patients without renal failure. However, a higher index of suspicion and a lower threshold for the initiation of a search is appropriate since patients with ESRD are frequently diabetic and/or immunosuppressed because of the retention of uremic toxins. Careful attention to appropriate dosing of antibiotics and the avoidance (if possible) of nephrotoxic drugs in the patient with residual renal function are also significant issues.

Many of the infections reviewed in this topic are not unique to the dialysis patient. As a result, although the likelihood of their occurrence may be increased, special considerations and guidelines for the dialysis patient are not available. Diagnostic and treatment strategies must be tailored to the individual patient, including the consequences of kidney failure and other comorbid conditions, the geographic location, and specific environmental exposures.

A review of the clinical characteristics of infections not related to the dialysis access is presented here. Reviews of access-related infections and the clinical manifestations and treatment of sepsis in dialysis patients, a complication most commonly due to infection of dialysis access devices, are discussed separately. (See "Tunneled, cuffed hemodialysis catheter-related bacteremia" and "Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access" and "Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis".)

EPIDEMIOLOGY

Data from the United States Renal Data System (USRDS) indicates that infections are a leading cause of death among patients with end-stage renal disease (ESRD) [1], accounting for approximately 15 percent of all fatalities [2]. The vast majority result from bacteremia/sepsis, followed by pulmonary infection [1].

Compared with the population with normal kidney function, patients with chronic kidney disease (CKD) and ESRD are at higher risk of contracting bacterial infections, particularly urinary tract infections, pneumonia, and sepsis [3,4].

                            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Jun 7, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 55(Suppl 1):S1.
  2. Survival, mortality, & causes of death. USRDS. United States Renal Data System. Am J Kidney Dis 2001; 38:S135.
  3. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13:199.
  4. Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59:356.
  5. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58:1758.
  6. Foley RN, Guo H, Snyder JJ, et al. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 2004; 15:1038.
  7. Khan IH, Catto GR. Long-term complications of dialysis: infection. Kidney Int Suppl 1993; 41:S143.
  8. Alexander D, Peacock E. Drug resistant organisms and their implications for the outpatient dialysis setting. Nephrol News Issues 1997; 11:27.
  9. Mc Causland FR, Brunelli SM, Waikar SS. Association of smoking with cardiovascular and infection-related morbidity and mortality in chronic hemodialysis. Clin J Am Soc Nephrol 2012; 7:1827.
  10. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int 2006; 70:1135.
  11. James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54:24.
  12. Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients--the United States Renal Data System. Nephrol Dial Transplant 2008; 23:680.
  13. Chen CH, Hsu WH, Chen HJ, et al. Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease. Chest 2007; 132:532.
  14. Lerner PI. Meningitis caused by Streptococcus in adults. J Infect Dis 1975; 131 Suppl:S9.
  15. Mansoor GA, Ornt DB. Cryptococcal peritonitis in peritoneal dialysis patients: a case report. Clin Nephrol 1994; 41:230.
  16. Smith JW, Arnold WC. Cryptococcal peritonitis in patients on peritoneal dialysis. Am J Kidney Dis 1988; 11:430.
  17. Yinnon AM, Solages A, Treanor JJ. Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993; 17:736.
  18. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364.
  19. Kuo CC, Lee CT, Lee IM, et al. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis 2012; 59:428.
  20. Wu MY, Hsu YH, Su CL, et al. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis 2012; 60:548.
  21. Polo JR, Luño J, Menarguez C, et al. Peritoneal mucormycosis in a patient receiving continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1989; 13:237.
  22. Hojs R. Cholecystolithiasis in patients with end-stage renal disease treated with haemodialysis: a study of prevalence. Am J Nephrol 1995; 15:15.
  23. Mirza MM, Wall BM. Emphysematous cholecystitis in a CAPD patient. Perit Dial Int 1997; 17:305.
  24. Ishikawa I, Chikamoto E, Nakamura M, et al. High incidence of common bile duct dilatation in autosomal dominant polycystic kidney disease patients. Am J Kidney Dis 1996; 27:321.
  25. Harwell CM, Newman LN, Cacho CP, et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int 1997; 17:586.
  26. Bárány P, Stenvinkel P, Nord CE, Bergström J. Clostridium difficile infection--a poor prognostic sign in uremic patients? Clin Nephrol 1992; 38:53.
  27. Cunney RJ, Magee C, McNamara E, et al. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant 1998; 13:2842.
  28. Eddi R, Malik MN, Shakov R, et al. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton) 2010; 15:471.
  29. Keddis MT, Khanna S, Noheria A, et al. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc 2012; 87:1046.
  30. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.
  31. Gilbert DN, Moellering RC, Sande MA. Table 17. In: The Sanford Guide to Antimicrobial therapy, 28th ed., Sanford, 1998. p.117.
  32. Cabaluna CC, Gary NE, Eisinger RP. Urinalysis in patients on chronic hemodialysis. Urology 1977; 10:103.
  33. Chaudhry A, Stone WJ, Breyer JA. Occurrence of pyuria and bacteriuria in asymptomatic hemodialysis patients. Am J Kidney Dis 1993; 21:180.
  34. Eisinger RP, Asghar F, Kolasa C, Weinstein MP. Does pyuria indicate infection in asymptomatic dialysis patients? Clin Nephrol 1997; 47:50.
  35. Orłowska A, Majdan M, Kozioł-Montewka M, et al. Asymptomatic bacteriuria in patients on continuous ambulatory peritoneal dialysis. Ann Univ Mariae Curie Sklodowska Med 2002; 57:285.
  36. Fasolo LR, Rocha LM, Campbell S, Peixoto AJ. Diagnostic relevance of pyuria in dialysis patients. Kidney Int 2006; 70:2035.
  37. D'Agata EM, Mount DB, Thayer V, Schaffner W. Hospital-acquired infections among chronic hemodialysis patients. Am J Kidney Dis 2000; 35:1083.
  38. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7:978.
  39. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989; 320:1188.
  40. Centers for Disease Control and Prevention (CDC). Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients--United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:197.
  41. Hadley AC, Karchmer TB, Russell GB, et al. The prevalence of resistant bacterial colonization in chronic hemodialysis patients. Am J Nephrol 2007; 27:352.
  42. Holley JL, Bernardini J, Johnston JR, Piraino B. Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program. Am J Kidney Dis 1990; 16:142.
  43. Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996; 156:1458.
  44. Roghmann MC, Fink JC, Polish L, et al. Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney Dis 1998; 32:254.
  45. Brady JP, Snyder JW, Hasbargen JA. Vancomycin-resistant enterococcus in end-stage renal disease. Am J Kidney Dis 1998; 32:415.
  46. Ng R, Zabetakis PM, Callahan C, et al. Vancomycin-resistant enterococcus infection is a rare complication in patients receiving PD on an outpatient basis. Perit Dial Int 1999; 19:273.
  47. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.
  48. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16:105.
  49. Medical Review Board Workgroup on VRE. Reducing the spread of vancomycin-resistant enterococcus in the dialysis setting. Mid-Atlantic Renal Coalition, 1996 Report.
  50. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.
  51. Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron 1996; 73:421.
  52. Taskapan H, Utas C, Oymak FS, et al. The outcome of tuberculosis in patients on chronic hemodialysis. Clin Nephrol 2000; 54:134.
  53. Lui SL, Tang S, Li FK, et al. Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2001; 38:1055.
  54. Centers for Disease Control and Prevention (CDC). Tuberculosis transmission in a renal dialysis center--Nevada, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:873.
  55. Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the kidney. J Am Soc Nephrol 2001; 12:1307.
  56. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16:38.
  57. Hung KH, Lee CT, Chen JB, Hsu KT. Tuberculous peritonitis in uremic patients. Clin Nephrol 2003; 60:113.
  58. Kriki P, Thodis E, Deftereos S, et al. A tumor-like manifestation of extrapulmonary tuberculosis in a hemodialysis patient. Clin Nephrol 2009; 71:714.
  59. Smirnoff M, Patt C, Seckler B, Adler JJ. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998; 113:25.
  60. Woeltje KF, Mathew A, Rothstein M, et al. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998; 31:848.
  61. Korzets A, Gafter U. Tuberculosis prophylaxis for the chronically dialysed patient--yes or no? Nephrol Dial Transplant 1999; 14:2857.
  62. Poduval RD, Hammes MD. Tuberculosis screening in dialysis patients--is the tuberculin test effective? Clin Nephrol 2003; 59:436.
  63. Wauters A, Peetermans WE, Van den Brande P, et al. The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant 2004; 19:433.
  64. Eleftheriadis T, Tsiaga P, Antoniadi G, et al. The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients. Am J Kidney Dis 2005; 46:706.
  65. Winthrop KL, Nyendak M, Calvet H, et al. Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008; 3:1357.
  66. Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 2010; 5:1114.
  67. Lee SS, Chou KJ, Dou HY, et al. High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test. Clin J Am Soc Nephrol 2010; 5:1451.